Cargando…

Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis

BACKGROUND: The purpose of the present meta-analysis was to compare the efficacy of rifaximin and nonabsorbable disaccharides (NADs) in hepatic encephalopathy (HE). METHODS: After the registration of the present meta-analysis on INPLASY, all procedures were performed according to PRISMA 2020. Releva...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Junxiong, Chen, Yafang, Cao, Wenfu, Zuo, Guoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701975/
https://www.ncbi.nlm.nih.gov/pubmed/34941089
http://dx.doi.org/10.1097/MD.0000000000028232
_version_ 1784621134141980672
author Cheng, Junxiong
Chen, Yafang
Cao, Wenfu
Zuo, Guoqing
author_facet Cheng, Junxiong
Chen, Yafang
Cao, Wenfu
Zuo, Guoqing
author_sort Cheng, Junxiong
collection PubMed
description BACKGROUND: The purpose of the present meta-analysis was to compare the efficacy of rifaximin and nonabsorbable disaccharides (NADs) in hepatic encephalopathy (HE). METHODS: After the registration of the present meta-analysis on INPLASY, all procedures were performed according to PRISMA 2020. Relevant literature was retrieved on PubMed, Embase, and the Cochrane Library up to September 5, 2021. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the enrolled studies, and Review Manager software (version 5.3) was used to analyze the clinical efficacy, blood ammonia and adverse effects. RESULTS: Six studies with 559 patients were included in the present meta-analysis. There were no significant differences in the basic characteristics of the included studies. Analysis of the complete resolution of HE showed that rifaximin was better than NADs (risk ratio [RR] = 1.87, 95% confidence interval [CI] = 1.03–3.39, P = .04). However, there were no significant differences in mental status (RR = 1.04, 95% CI = 0.92–1.18, P = .53), blood ammonia level (standard mean difference = −0.02, 95% CI = −0.40–0.02, P = .08), or drug adverse drug effects (OR = 0.43, 95% CI = 0.10–1.77, I(2) = 56%, P = .24) between the rifaximin and NADs treatment groups. CONCLUSION: Rifaximin is not superior to NADs in the treatment of HE.
format Online
Article
Text
id pubmed-8701975
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-87019752021-12-27 Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis Cheng, Junxiong Chen, Yafang Cao, Wenfu Zuo, Guoqing Medicine (Baltimore) 4500 BACKGROUND: The purpose of the present meta-analysis was to compare the efficacy of rifaximin and nonabsorbable disaccharides (NADs) in hepatic encephalopathy (HE). METHODS: After the registration of the present meta-analysis on INPLASY, all procedures were performed according to PRISMA 2020. Relevant literature was retrieved on PubMed, Embase, and the Cochrane Library up to September 5, 2021. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the enrolled studies, and Review Manager software (version 5.3) was used to analyze the clinical efficacy, blood ammonia and adverse effects. RESULTS: Six studies with 559 patients were included in the present meta-analysis. There were no significant differences in the basic characteristics of the included studies. Analysis of the complete resolution of HE showed that rifaximin was better than NADs (risk ratio [RR] = 1.87, 95% confidence interval [CI] = 1.03–3.39, P = .04). However, there were no significant differences in mental status (RR = 1.04, 95% CI = 0.92–1.18, P = .53), blood ammonia level (standard mean difference = −0.02, 95% CI = −0.40–0.02, P = .08), or drug adverse drug effects (OR = 0.43, 95% CI = 0.10–1.77, I(2) = 56%, P = .24) between the rifaximin and NADs treatment groups. CONCLUSION: Rifaximin is not superior to NADs in the treatment of HE. Lippincott Williams & Wilkins 2021-12-23 /pmc/articles/PMC8701975/ /pubmed/34941089 http://dx.doi.org/10.1097/MD.0000000000028232 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 4500
Cheng, Junxiong
Chen, Yafang
Cao, Wenfu
Zuo, Guoqing
Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
title Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
title_full Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
title_fullStr Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
title_full_unstemmed Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
title_short Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
title_sort is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: a meta-analysis
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701975/
https://www.ncbi.nlm.nih.gov/pubmed/34941089
http://dx.doi.org/10.1097/MD.0000000000028232
work_keys_str_mv AT chengjunxiong isrifaximinbetterthannonabsorbabledisaccharidesinhepaticencephalopathyametaanalysis
AT chenyafang isrifaximinbetterthannonabsorbabledisaccharidesinhepaticencephalopathyametaanalysis
AT caowenfu isrifaximinbetterthannonabsorbabledisaccharidesinhepaticencephalopathyametaanalysis
AT zuoguoqing isrifaximinbetterthannonabsorbabledisaccharidesinhepaticencephalopathyametaanalysis